Use of health technology assessment in drug reimbursement decisions in China

Two errors occurred in this article by Wen Chen and colleagues (BMJ 2023;381:e068915; doi:). In the first sentence of the second paragraph under the heading “Two stage appraisal process” the number of drugs that qualified under quick review should be 117 not 271. In the paragraph on preliminary progress, negotiated drugs were reimbursed 140 million not 14 million times in 2021. These errors have been corrected in the online version.